DTC Ad Delay Pending Collection Of Post-Marketing Data Endorsed By ASHP
Executive Summary
Direct-to-consumer advertising should be delayed for new drug products pending analysis of post-marketing surveillance data, the American Society of Health-System Pharmacists suggested at an FDA public hearing Nov. 1-2
You may also be interested in...
Is A Picture Worth A Thousand Words? – FDA Evaluation Of DTC Images Urged
FDA should consider the impact of images on consumer behavior as part of its evaluation of direct-to-consumer advertisements, the National Research Center for Women & Families suggested
Is A Picture Worth A Thousand Words? – FDA Evaluation Of DTC Images Urged
FDA should consider the impact of images on consumer behavior as part of its evaluation of direct-to-consumer advertisements, the National Research Center for Women & Families suggested
FDA Needs Health Communications Advisory Cmte. For DTC Policy, Pitts Says
An advisory committee on healthcare communications should be created to inform FDA's direct-to-consumer advertising policies, former FDA Associate Commissioner For External Relations Peter Pitts suggested at an FDA public hearing on DTC advertising Nov. 1-2